BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences to $80 from $85 but keeps a Buy rating on the shares. The company delivered a 1.6% Q1 revenue beat and reiterated its guidance, making the post-earnings decline “perplexing”. BTIG adds that it would recommend for investors to buy the stock on the weakness as it trades at close to 3-times next-12-months’ expected revenue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- EXAS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- Exact Sciences Announces Board Member Retirement
- Exact Sciences CFO’s resume ‘impressive,’ says William Blair
- Exact Sciences Appoints Aaron Bloomer as New CFO